© 2020 MJH Life Sciences and Practical Cardiology. All rights reserved.
Rates of Stress Cardiomyopathy Rising During COVID-19 Pandemic
July 09, 2020
By Patrick Campbell
Hyung Chun, MD: Cause of Blood Clots in COVID-19
July 09, 2020
By Patrick Campbell
Quitting Smoking Drastically Improves Survival After Heart Attack
July 08, 2020
By Patrick Campbell
Statin Use in Elderly Linked to Decrease in Risk of Death, Cardiovascular Mortality
July 07, 2020
By Patrick Campbell
Onset Timing, Severity of Menopausal Symptoms Help Predict Increased CVD Risk
July 07, 2020
By Patrick Campbell
Black Patients at Greater Risk of MACE Following PCI
July 06, 2020
An analysis of 10 randomized clinical trials is shedding new light on the risk of MACE seen by Black patients following PCI versus risk among white counterparts.
Tirofiban Bests Cangrelor for Inhibiting Platelet Aggregation in FABOLUS-FASTER Study
June 30, 2020
Results of the FABOLUS-FASTER trial indicate tirofiban may be more effective than cangrelor in reducing risk of acute ischemic complications when used for bridging platelet inhibition in heart attack patients undergoing percutaneous coronary intervention.
Image IQ: 13-Year-Old Complains of Abdominal Pain, Red Dots, and Overheating
June 30, 2020
How good are your diagnostic skills? Test them here with this month's Visual Dx quiz!
Increased Risk of Ischemic Heart Disease Associated With Pre-Term Deliveries
June 29, 2020
New research from an analysis of the Swedish Medical Birth Registry suggests women experience preterm delivery were at an increased risk of developing ischemic heart disease later in life.
Rivaroxaban Post-Discharge Reduces Thromboembolic Events in Acutely Ill Patients
June 25, 2020
Results of an exploratory analysis of the phase 3 MARINER study indicates post-discharge prophylaxis with rivaroxaban (Xarelto) could reduce the risk of both fatal and major thromboembolic events in medically ill patients.
ADA 2020: Decreasing Risk of Heart Failure Hospitalization With Empagliflozin
June 23, 2020
Findings of a recent study suggest empagliflozin is associated with a decreased risk of hospitalization for heart failure and a similar risk of myocardial infarction or stroke in routine clinical care.
For Diabetics, Heart Failure Associated With Worst Prognosis Among CVDs, CKD
June 23, 2020
New research suggests development of heart failure is associated with the greatest risk of death among type 2 diabetics with cardiovascular conditions.
AHA Awards Nonprofit Grants to Address Food and Healthcare Shortages Due to COVID-19
June 17, 2020
Twenty two nonprofit organizations have been awarded COVID-19 Rapid Response Grants as part of the American Heart Association’s Voices for Healthy Kids initiative.The grants range from $20,000 to $50,000 and will support work focused on improving access to healthy food, increasing access to health care and addressing income needs during and beyond the pandemic.
Diabetes Trial Shows Prevention Benefits Two Decades Later
June 16, 2020
New data released today from the Diabetes Prevention Program Outcomes Study (DPPOS) shows that in over 2000 patients followed for an average of 22 years, lifestyle programs and treatment with metformin continues to prevent the development of type 2 diabetes (T2D) in at risk populations.
Type 1 Diabetes Triggered First Two Years of Life, Research Says
June 15, 2020
New data from the Environmental Determinants of Diabetes in the Young (TEDDY) study illuminate the environmental triggers that are thought to cause the autoimmune response leading to type 1 diabetes(T1D) and celiac disease. The research, presented in a symposium at the American Diabetes Association meeting.shows that the destruction of the beta cells begins in the first two years of life.